CN1068227C - Interferon liposome jellies - Google Patents
Interferon liposome jellies Download PDFInfo
- Publication number
- CN1068227C CN1068227C CN97109123A CN97109123A CN1068227C CN 1068227 C CN1068227 C CN 1068227C CN 97109123 A CN97109123 A CN 97109123A CN 97109123 A CN97109123 A CN 97109123A CN 1068227 C CN1068227 C CN 1068227C
- Authority
- CN
- China
- Prior art keywords
- interferon
- liposome
- jellies
- interferon liposome
- ifn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to an interferon liposome gelling agent which is a novel interferon product which can be used for treating pointed condyloma of sexually-transmitted diseases. The interferon liposome gelling agent contains interferon liposome and gel, and the present invention has the advantages of long storage time, good water solubility and durable drug effect.
Description
The invention belongs to the novel product of interferon (IFN).
IFN is the new biological product of a kind of broad-spectrum antiviral, antitumor and tool immunoloregulation function, a large amount of clinical trials prove, IFN has certain therapeutic effect to about 30 kinds of viral diseases with by the oncosis that virus causes, think in the evaluation to the IFN curative effect in 1992 of WHO expert group that wart is the most effective a kind of in the various viral infection of IFN clinical treatment.
As everyone knows, condyloma acuminatum is a kind of proliferative disease that is caused by human papillomavirus, and infectiousness is very strong, and severe patient can cause canceration.The method of treatment condyloma acuminatum is varied now, traditional is to be purpose to remove exophytic wart, to destroy that macroscopic local disease decreases with laser, freezing, physiotherapy such as fulgerize and some chemotherapy, rather than elimination human papillomavirus, relapse rate is very high, and during the treatment, redness often arranged, fester, side reaction and some contraindications such as pain, make the patient feel inconvenience and frightened.At the recurrence problem, in recent years, many experts and scholars have carried out unremitting exploration and research to this, and the success for the treatment of recurrent condyloma acuminatum with IFN is that this disease of radical cure has been brought hope and dawn.Yet, in the currently used IFN Therapeutic Method, intramuscular injection, this systemic administration mode of subcutaneous injection, the IFN dosage is big, the cycle long, expensive medical expenses make many patients can't adhere to treatment.Decrease position injection IFN in disease, though wart body no pain is come off, powerless to the subclinical infringement and the pathogen of hiding; The IFN wiring solution-forming is carried out part spraying or dip in IFN liquid with tiny cotton swab and embrocate the affected part, make curative effect unsatisfactory because of easily problem such as being wiped after unresolved IFN stability problem, Transdermal absorption problem, the medication by underwear.With IFN and CO
2Laser, physiotherapy therapeutic alliance such as fulgerize, though curative effect is better, the wart body that the contraindication of physiotherapy, side effect and focus area are big must adopt problem such as gradation operation to bring many inconvenience and worry to the patient.At above situation, seek the best form of administration of a kind of IFN and close at hand.
Foreign literature has reported that liposome is used for the treatment of human papillomavirus as external medicament carrier parcel IFN and infects.We find under study for action, the IFN liposome can solve IFN Transdermal absorption problem effectively, but after the medication with mucosa can not strong bonded performance curative effect and easily being wiped by underwear, reduce its curative effect greatly, and be colloidal after the dehydration of IFN liposome, do not use water dissolution if having Special Equipment before using, for up to a couple of days, if shorten greatly because of the interferon stability problem makes storage life with the aqueous solution state preservation.
The object of the present invention is to provide a kind of interferon liposome jellies, it has the storage life efficacy stability, lasting medicine during use, good water solubility, advantage easy to use.
Interferon liposome jellies of the present invention is characterized in that it contains one of interferon liposome and following gel in essence: hypromellose, hyprolose, carmethose, polyvinyl alcohol.
As above-mentioned interferon liposome jellies, it is characterized in that their component is: interferon liposome 5-200mg contains interferon alpha-2 0-500 ten thousand iu, the 5-100mg gel.
As above-mentioned interferon liposome jellies, it is characterized in that their component is:
Interferon liposome 10-80mg contains interferon 100-350 ten thousand iu
Gel 10-30mg
Interferon of the present invention can be natural, engineered α, β, γ type.
Described gel can be: hypromellose, hyprolose, carmethose, polyvinyl alcohol.Wherein, be best with hypromellose again, the long 2-3 of time of other gels of time ratio that its film exists on epidermis doubly can reach more than 12 hours.
The present invention is with gel and interferon liposome combination, make interferon liposome after dehydration, become powdery, interferon liposome can long preservation, again can be soluble in water rapidly in 2 minutes during use, gel makes aqueous solution become gel solution after soluble in water simultaneously, this solution can form the film of one deck water proof every air after being applied to human epidermal on skin, interferon liposome is not wiped by underwear, thereby improves the effective rate of utilization of medicine.This film is very thin, and user does not have foreign body sensation.
Embodiments of the invention are as follows:
Prescription: (in every bottle of 3ml)
Interferon liposome 30mg contains interferon 3,000,000 iu
Hypromellose 25mg
Mannitol 25mg
Ethanol 3ml (75%)
Wherein, ethanol is as the solvent of hypromellose;
Mannitol: in the film of hypromellose, play filler effect, increase thickness, the protectiveness of film is improved.
Method for making:
1. system interferon liposome: get lecithin 2.5mg, cephalin 0.25mg, cholesterol 2.5mg, three add in the chloroform of 50mg, and stirring and dissolving adds 3,000,000 iu interferon liquids, makes the 30mg interferon liposome with solvent evaporated method.
2. get the 25mg hypromellose, be dissolved in 3ml ethanol (75%) after, add 25mg mannitol, under 0-4 ℃ of aseptic condition, mix mutually with interferon liposome, become interferon liposome jellies after the lyophilization, be shaped as the microgranule powdery.
Above-mentioned interferon liposome jellies is a powdery when preserving, and pours into before the use in the water and can all dissolve about 2 minutes.Gel aqueous solution of the present invention uses as medicine for external application.
Interferon liposome jellies of the present invention has economy, safety, convenience, high, the secondary work of poison of curative effect than other administering mode With the advantage such as little. It can make the wart body rapidly no pain come off, and can suppress to hide pathogen, the division that suppresses virus copies, Improve body immunity, reach the curative effect of pulling the grass up by its roots. The new gel that adds had both played and had separated the interferon liposome dewatering state Adhesion, film forming is not wiped by underpants in human epidermal protection medicine when using after dissolving in water again, has improved widely interferon The result of use of liposome.
In addition, the main ingredient IFN of this gel, it has broad-spectrum disease resistance toxicity, except effecting a radical cure the condyloma acuminatum, to other virus The disease of venereal disease because causing, as: herpes zoster, the flat wart, verruca vulgaris etc. also have unique curative effect, and it can simultaneously The canceration that prevention and treatment are caused by virus.
Claims (3)
1. interferon liposome jellies is characterized in that it mainly contains one of interferon liposome and following gel: hypromellose, hyprolose, carmethose, polyvinyl alcohol.
2. interferon liposome jellies as claimed in claim 1 is characterized in that their component is; Interferon liposome 5～200mg contains interferon alpha-2 0～5,000,000 iu, 5～100mg gel.
3. interferon liposome jellies as claimed in claim 2 is characterized in that their component is:
Interferon liposome 10～80mg contains interferon 100～3,500,000 iu
Gel 10～30mg
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97109123A CN1068227C (en) | 1997-05-29 | 1997-05-29 | Interferon liposome jellies |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97109123A CN1068227C (en) | 1997-05-29 | 1997-05-29 | Interferon liposome jellies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1200942A CN1200942A (en) | 1998-12-09 |
| CN1068227C true CN1068227C (en) | 2001-07-11 |
Family
ID=5170938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97109123A Expired - Fee Related CN1068227C (en) | 1997-05-29 | 1997-05-29 | Interferon liposome jellies |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1068227C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100344324C (en) * | 2004-01-16 | 2007-10-24 | 深圳市海王英特龙生物技术股份有限公司 | Cream of liposome of interferon |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1557479A (en) * | 2004-01-16 | 2004-12-29 | 深圳市海王英特龙生物技术股份有限公 | Interferon liposome emulsifiable paste |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989005149A1 (en) * | 1987-12-03 | 1989-06-15 | The Liposome Company, Inc. | Methyl cellulose pharmaceutical composition |
| WO1995003789A1 (en) * | 1993-07-28 | 1995-02-09 | The Johns Hopkins University School Of Medicine | Controlled release of pharmaceutically active substances from coacervate microcapsules |
-
1997
- 1997-05-29 CN CN97109123A patent/CN1068227C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989005149A1 (en) * | 1987-12-03 | 1989-06-15 | The Liposome Company, Inc. | Methyl cellulose pharmaceutical composition |
| WO1995003789A1 (en) * | 1993-07-28 | 1995-02-09 | The Johns Hopkins University School Of Medicine | Controlled release of pharmaceutically active substances from coacervate microcapsules |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100344324C (en) * | 2004-01-16 | 2007-10-24 | 深圳市海王英特龙生物技术股份有限公司 | Cream of liposome of interferon |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1200942A (en) | 1998-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004251720B2 (en) | Method for treatment of sores and lesions of the skin | |
| JP2004507496A5 (en) | ||
| US5744167A (en) | Methods for the treatment of herpes virus infections | |
| US7737130B2 (en) | Pharmaceutical compositions for topical use in treatment of skin or mucous injuries | |
| EP2501366B1 (en) | Anti-viral composition | |
| CN101874809A (en) | Local anti-inflammatory external medicinal composition using glycerol DMSO mixed solvent | |
| US7807656B2 (en) | Pharmaceutical applications of hyaluronic acid preparations | |
| JPH01503146A (en) | Methods of treating body tissue and administering medicines to body tissue | |
| CN1068227C (en) | Interferon liposome jellies | |
| CN1049142C (en) | Qufushengjisan powder medicine capable of removing putrid tissues and promoting growth of new tissues and shengjisan powder | |
| CN1895381A (en) | Tissue regenerating ointment with repercussive and toxin-draining functions | |
| WO2017181978A1 (en) | Mussel adhesive protein product and use of same for inhibiting vascular inflammation | |
| CN1058154C (en) | Medicine for treatment of pile | |
| CN1634429A (en) | Medicine composition for treating furuncle, abscess, carbuncle, furuncle, burn and scald | |
| US20070032558A1 (en) | Method of treating herpes viral infections using a halogenated hydrocarbon composition | |
| CN1524555A (en) | Exterior-applied Chinese herbal medicine preparation for traumatic infection and inflammation-relieving acesodyne and its preparation method | |
| CN112316108A (en) | Compositions and methods for promoting and treating chronic wound healing | |
| CN1127970C (en) | Ointment for treating burn and its preparing process | |
| CN1066944C (en) | Ointment for burn and scald | |
| KR20200084814A (en) | Composition for lipolysis and cellulite improvement, and the kit comprising the same | |
| CA2126704C (en) | Dermatological compositions and methods for the treatment of skin therewith | |
| CN1258367C (en) | Medicine for treating trauma | |
| CN108635362A (en) | A kind of pharmaceutical composition for treating diabetes | |
| CN106729631A (en) | Treat the externally applied spray of intractable skin ulcer | |
| CN113713000B (en) | Main medicine component composition for treating sore carbuncle, burn, scald and acne, sustained and controlled release pharmaceutical preparation, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |